dal-OUTCOMES

In dal-OUTCOMES, modest CETP inhibition and raising of HDL cholesterol (by 30%) did not reduce cardiovascular outcomes in ACS patients. Dalcetrapib was terminated on 7 May 2012.
1 2
3 4
4 4
4 4
4
Download Slides (.ppt)

Editors

REGISTRATION IS FREE TO ALL HEALTHCARE PROFESSIONALS

 Supported by unrestricted medical
educational grants from

 Supporters have no editorial influence
over the content of this website